In 2023, Ari Bousbib earned $34.68M in total compensation at IQVIA, including $1.80M salary, $4.78M bonus and $28.10M in stock. Most recently acquired 44,000 shares in Jan 2025. Currently holds stock worth $193.05M. 9+ years at the helm of IQVIA.
Compensation History
Annual executive compensation data for Ari Bousbib, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$34.68M
Salary
$1.80M
Bonus
$4.78M
Other
$0.00
Salary
$1.80MBoard Justification
The compensation philosophy focuses on aligning executive compensation with business performance, rewarding achievement of financial, strategic, operational, leadership, and ESG goals to contribute to long-term stockholder value.
Bonus
$4.78MBoard Justification
The bonus is based on a target incentive of 200% of base salary, with a formula-based performance payout factor of 118% and an individual performance adjustment of 11.5%.
Other Compensation
$0.00Board Justification
No other compensation was reported for 2023.
Restricted Stock
Board Justification
The stock that vested in 2023 includes performance shares earned based on the achievement of performance goals for the 2021-2023 performance period, with a total of 101,784 shares vesting on December 31, 2023.
Performance Metrics
The performance metrics for determining Ari Bousbib's compensation include Revenue/Profit, Cash Flow, Balance Sheet/Liquidity, Operational/Strategic, and Leadership/Sustainability.
Ari Bousbib
CEO of IQVIA
Education
MBA from Columbia University, Master of Science in Mathematics and Mechanical Engineering from Ecole Superieure des Travaux Publics, Paris
Field of Expertise
Business & Management
Sector of Economy
Healthcare
Born
January 1, 1961 - 64 years ago
CEO of IQVIA for
9 years 7 months (May 2016 - Present)
Previous Experience
CEO of IMS Health, President of UTC's Commercial Companies, partner at Booz Allen Hamilton
Holdings
Track Ari Bousbib's stock holdings and portfolio value over time.
Total Stock Sold
$190.58M
$190.58M
1,337,278 IQV shares
What if they kept their stock?
If Ari Bousbib didn't sell their stock, today they would have:
Extra IQV1,337,278 shares worth $300.78M.
This is 57.82% and $110.20M more than what they got when they sold the stock.
Insider Trading
Ari Bousbib's recent stock transactions, purchases, and sales filed with the SEC.
44,000 shares
IQV
Jan 28, 2025
Received
$7.94M
IQV at $250.54/share
Mar 1, 2024
Sale
86,912 shares
IQV
Feb 6, 2024
Received
87,459 shares
IQV
Feb 7, 2023
Received
20,542 shares
IQV
Feb 10, 2022
Received
91,142 shares
IQV
Feb 9, 2022
Received
97,577 shares
IQV
Feb 9, 2021
Received
$576.46K
IQV at $8.34/share
Oct 12, 2020
Received
$11.75M
IQV at $170.00/share
Oct 12, 2020
Sale
$384.31K
IQV at $8.34/share
Sep 15, 2020
Received
Rivals
Compare Ari Bousbib with competitor CEOs and industry peers.
Patrick Kaltenbach
CEO of Mettler-Toledo International, Inc.
2023 Compensation
Stock
$0.00
Salary
$1.00M
Bonus
$155.16K
Other
$355.86K
Total Holdings
$7.79M
Olivier A. Filliol
CEO of Mettler-Toledo International, Inc.
2023 Compensation
Stock
$0.00
Salary
$26.67K
Bonus
$11.93K
Other
$11.93K
Total Holdings
$26.26M
August J. Troendle
Founder and CEO of Medpace Holdings, Inc.
2023 Compensation
Stock
$0.00
Salary
$825.00K
Bonus
$814.42K
Other
$17.33K
Total Holdings
$513.58M
James C. Foster
CEO of Charles River Laboratories
2023 Compensation
Stock
$0.00
Salary
$1.48M
Bonus
$1.13M
Other
$71.89K
Total Holdings
$582.93K